Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence
This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
- Signed and dated written informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
- One of the following current diagnoses: * Stage IIa to III triple negative breast cancer (TNBC). * Stage I to III pancreatic adenocarcinoma. * Lung Cancer. ** Stage IIa to III non-small cell lung cancer (NSCLC). ** Limited stage small cell lung cancer (SCLC). * Stage IIa to III esophageal or gastroesophageal (GE) junction cancers (squamous cell carcinoma [SCCA] or adenocarcinoma) (or esophageal or GE junction cancer stages I to III considered to be at high risk for metastatic recurrence per the treating physician's discretion). * Stage IIa to III stomach cancer (or stomach cancer stages I to III considered to be at high risk for metastatic recurrence per the treating physician's discretion).
- Patients must have completed all standard locoregional and systemic therapy for their cancer within 120 days of study enrollment.
- Administration of an investigational agent prior to enrollment needs to be completed at least 30 days prior to enrollment.
- Patients must have recovered (=< grade 1 toxicities or grade 2 toxicities well managed with optimal medical care) from effects of local (surgery, radiation) or systemic treatments.
- Platelet count >= 100,000 per mL of blood.
- Hemoglobin >= 9/g/dL (may have been transfused).
- Serum creatinine =< 1.5 x upper limit of normal (ULN) or estimated creatinine clearance >= 50 mL/min as calculated using the Cockcroft-Gault (CG) equation.
- Total serum bilirubin =< 1.5 times upper limit of normal (ULN).
- Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT/serum glutamate-pyruvate transaminase [SGPT]) =< 2.5 x ULN.
- International normalized ratio (INR) below upper limit of normal (ULN).
- Female patients of childbearing potential and non-sterile males must agree to use at least two methods of acceptable contraception from 15 days prior to first trial treatment administration until at least 5 months after study participant’s final dose of study drug. * Note: Females of childbearing potential are defined as those who are not surgically sterile or post-menopausal (i.e. patient has not had a bilateral tubal ligation, a bilateral oophorectomy, or a complete hysterectomy; or has not been amenorrheic for 12 months without an alternative medical cause). Post-menopausal status in females under 55 years of age should be confirmed with a serum follicle-stimulating hormone (FSH) level within laboratory reference range for postmenopausal women. Non-sterile males are those who have not had a vasectomy with documentation of the absence of sperm in the ejaculate.
- Patients unable to read/write in English are eligible to participate in the overall study but will not participate in the Patient-Reported Outcome questionnaires throughout the trial.
- Re-enrollment of a subject that has discontinued the study as a pre-treatment screen failure (i.e. a consented patient who did not receive study drugs) is permitted. If reenrolled, the subject must be re-consented. Only the screening procedures performed outside of protocol-specified timing must be repeated.
- Evidence of biopsy-proven distant metastatic disease after completion of standard treatment.
- Current use of anti-platelet drugs (acetylsalicylic acid [ASA], nonsteroidal anti-inflammatory drugs [NSAIDs], clopidogrel, argatroban, etc.) or anticoagulants (warfarin, heparin products, etc.).
- Active malignancy within 5 years prior to current diagnosis except for in situ disease or cancer with very high curability rate (i.e. testicular cancer, etc.).
- Uncontrolled co-morbid serious systemic illnesses that in the opinion of the investigator could compromise therapeutic safety.
- No concurrent anticancer therapy. Required washout from prior therapy: * Chemotherapy: 21 days. * Major surgery: 14 days (provided wound healing is adequate). * Radiation: 7 days. * Investigational/Biologic Therapy: 30 days.
- Current symptomatic congestive heart failure (New York Heart Association > class II), unstable cardiac arrhythmia requiring therapy (e.g. medication or pacemaker), unstable angina (e.g. new, worsening or persistent chest discomfort), or uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100mmHg). Or any of the following occurring within 6 months (180 days) prior to first dose of study drugs: Myocardial infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack. (Use of antihypertensive medication to control blood pressure is allowed.)
- Ongoing peptic ulcer disease requiring treatment.
- History of gastrointestinal bleed.
- Severe gastro-esophageal reflux disease requiring treatment.
- History of bleeding diathesis.
- Planned elective major surgical intervention while taking ifetroban.
- Pregnant or breastfeeding females.
- Prisoners or subjects who are involuntarily incarcerated.
- Known psychiatric condition, social circumstance, or other medical condition reasonably judged by the patient’s study physician to unacceptably increase the risk of study participation; or to prohibit the understanding or rendering of informed consent or anticipated compliance with scheduled visits, treatment schedule, laboratory tests and other study requirements.
Locations & Contacts
Contact: Ingrid Alina Mayer
Trial Objectives and Outline
I. To assess the safety and feasibility of ifetroban sodium (ifetroban) administration in patients with malignant solid tumors at high risk of metastatic recurrence, after completion of all planned (neo)adjuvant locoregional and systemic therapies.
I. To assess rate of metastatic recurrence after completion of ifetroban in patients with malignant solid tumors.
I. To quantify pharmacodynamic markers of ifetroban effects.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP 1 (IFETROBAN): Patients receive ifetroban sodium orally (PO) once daily (QD). Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
GROUP 2 (PLACEBO): Patients receive a placebo PO QD. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then up to 12 months.
Trial Phase & Type
Vanderbilt University / Ingram Cancer Center
Ingrid Alina Mayer
Secondary IDs NCI-2018-01930
Clinicaltrials.gov ID NCT03694249